ArticleJournal of nutrition and metabolism2026
Milk-Derived Kefir Improves Cardiac Function in Female Rats Subjected to Myocardial Infarction.
Article in Journal of nutrition and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases remain a major global health burden, with myocardial infarction (MI) being a leading cause of mortality and long-term disability. Kefir, a fermented milk beverage rich in probiotic and bioactive compounds, has demonstrated cardioprotective effects in experimental models of hypertension. However, its effects in MI induced by coronary artery ligation remain poorly understood. This study investigated the impact of chronic kefir administration on cardiac function and remodeling in female Wistar rats subjected to MI. Animals were allocated to three groups: sham-operated (S), infarct vehicle-treated (IV), and infarct kefir-treated (IK). Treatments were administered daily for 60 days. Hemodynamic parameters, infarct area, collagen deposition, oxidative stress markers, and morphometric changes were evaluated. Chronic kefir treatment significantly reduced left ventricular end-diastolic pressure (LVEDP), infarct area, and collagen deposition in infarcted animals. Kefir also improved hemodynamic parameters by reducing systolic, diastolic, and mean arterial pressures while increasing heart rate. In addition, oxidative stress was attenuated, as evidenced by lower levels of advanced oxidation protein products (AOPP). No evidence of systemic toxicity or organ hypertrophy was observed. These findings suggest that milk-derived kefir exerts cardioprotective effects by improving hemodynamic function, attenuating adverse cardiac remodeling, and reducing oxidative stress. Collectively, the results support the potential of kefir as an adjunctive strategy for improving cardiac recovery following MI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.